AbbVie Dividend Growth Faces Humira Sales Decline

AbbVie Inc. (NYSE: ABBV) shareholders received a 5.5% increase in their quarterly dividend, now set at $1.73 per share. This payout hike occurs as the company grapples with a significant revenue drop from its once-dominant drug, Humira, which saw sales fall 36%. The pharmaceutical giant is leveraging its substantial free cash flow, reported at $17.8 billion annually, to maintain and grow its shareholder distributions despite the erosion of its legacy franchise.

This strategy is playing out against a backdrop of evolving market dynamics, including the impact of the Inflation Reduction Act's (IRA) pricing pressures on drugs like Imbruvica, which fell 29.4%. While Skyrizi and Rinvoq are showing strong growth, with Skyrizi achieving 24% growth and Rinvoq 23.7% growth respectively, and overall revenue reaching $17 billion at 10.2% growth, the specter of patent cliffs looms. Skyrizi itself faces patent expiry in 2033, suggesting a potential repeat of the Humira transition.

Despite the challenges, AbbVie's stock has seen considerable gains, climbing 53.59% since the start of 2024. The company's ability to generate strong free cash flow, evidenced by $19.03 billion in operating cash flow against $1.21 billion in capex in fiscal 2025, supports its dividend. The free-cash-flow payout ratio remains in the mid-60s, contributing to a 3.88% free cash flow yield. Management has also guided for 2026 adjusted EPS between $13.87 and $14.07, which comfortably covers the annualized dividend.